Hematologic Oncology | Specialty

Selecting a TKI in Subsequent Lines of Therapy in CML

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Dosing Strategies for Ponatinib in CML and ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

Emerging Mutation Analysis from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma

January 22nd 2025

IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML

January 22nd 2025

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.

Dr Daver on the Potential Role for Menin Inhibitors in Frontline AML

January 17th 2025

Naval G. Daver, MD, discusses the potential role for menin inhibitors in the frontline treatment of patients with acute myeloid leukemia.

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

January 16th 2025

The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden

January 13th 2025

Naseema Gangat, MBBS, discusses the role of rusfertide for decreasing phlebotomy needs and the potential future for disease-modifying PV management.

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

January 12th 2025

Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

January 10th 2025

Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

Hodgkin Lymphoma: Overview and Update

January 8th 2025

Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.

Frontline Treatment Considerations in Adult and Pediatric Acute Lymphoblastic Leukemia

January 8th 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.

Dr DeAngelo on the Effect of Avapritinib on Bone Density in Advanced Systemic Mastocytosis

January 7th 2025

Daniel DeAngelo, MD, PhD, discusses the effect of avapritinib on bone density in patients with advanced systemic mastocytosis.

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

January 7th 2025

Armin Ghobadi, MD, discusses the safety profile of WT-7 in heavily pretreated relapsed/refractory T-ALL and LBL.

Dr Emadi on Initial Responses With Venetoclax Plus PegC in R/R AML

January 6th 2025

Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.

Dr Riedell on Efficacy and Safety of Rapcabtagene Autoleucel in R/R DLBCL

January 3rd 2025

Peter Riedell, MD, discusses efficacy and safety of rapcabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma

December 31st 2024

After answering her calling for hematology oncology, Margaret A. Shipp, MD, shook up lymphoma research by exploiting the PD-1 pathway to evade immune detection and testing checkpoint inhibitors across this malignancy, among several other achievements.